Trial Profile
Case register study to capture the efficacy of Ipilimumab and other therapies after treatment with Nivolumab or Pembrolizumab in Ipilimumab naive patients with stage IV or non-resectable stage III metastatic melanoma - PD-Next
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 25 Jun 2018
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Acronyms PD-Next
- 25 Jun 2018 New trial record